Figure 2. Molecular expression changes induced by bromodomain-containing 4 (BRD4) inhibitor I-BET151 in mantle cell lymphoma (MCL)-derived cell lines. A: Venn diagrams showing the numbers of genes up-regulated by more than 1.5-fold or down-regulated by less than 0.67-fold, respectively, in JVM-2 and Z138 cells treated with I-BET151. B: Average fold change in relative expression of 665 commonly down-regulated genes in JVM-2 and Z138 cells after I-BET151 treatment as identified by microarray analysis are illustrated with the annotation of genes associated with B-cell biology. C: Quantitative reverse transcription-polymerase chain reaction identified genes associated with B-cell biology and MYC. Cells were treated with their respective 80% inhibitory concentrations (IC₈₀s) with I-BET151 for the indicated periods. Significantly different at *p<0.05 and **p<0.01 compared with untreated cells (t-test). D: Western blot analyses. Cells were treated with their respective 50% inhibitory concentrations (IC₅₀s) or IC₈₀s for I-BET151 for the indicated periods. Non-specific bands are indicated by arrowheads. Ctrl: Untreated cells.